<DOC>
	<DOCNO>NCT02281357</DOCNO>
	<brief_summary>A Multicentre , Randomized , Double-blind , Parallel Group , Placebo Controlled , Phase 3 Study Evaluate Efficacy Safety Tralokinumab Reducing Oral Corticosteroid dependent Asthma .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Efficacy &amp; Safety Tralokinumab Adults &amp; Adolescents With OCS Dependent Asthma</brief_title>
	<detailed_description>This randomize , double-blind , parallel group , placebo-controlled study design evaluate efficacy safety fix 300 mg dose tralokinumab administer subcutaneously every 2 week adult adolescent subject oral corticosteroid dependent asthma . Approximately120 subject randomize globally . Subjects receive tralokinumab placebo , administer via subcutaneous injection study site , 40-week treatment period .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 ) Age 1275 2 ) Documented physiciandiagnosed asthma . 3 ) Documented treatment ICS total daily dose correspond ≥500µg fluticasone propionate dry powder formulation LABA . 4 ) Subjects must receive OCS treatment asthma 6 month prior Visit 1 stable OCS dose ≥7.5 ≤30mg daily daily equivalent least one month prior enrolment ( Visit 1 ) . 5 ) PreBD FEV1 value &lt; 80 % ( &lt; 90 % patient 1217 yr age ) PNV . 6 ) PostBD reversibility ≥12 % FEV1 . 1 ) Clinically important pulmonary disease asthma . 2 ) History anaphylaxis follow biologic therapy . 3 ) Hepatitis B , C HIV . 4 ) Pregnant breastfeeding . 5 ) History cancer . 6 ) Current tobacco smoke history tobacco smoke ≥10 packyears . 7 ) Previous receipt tralokinumab .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Reactive Airways</keyword>
	<keyword>Repiratory Tract Disease</keyword>
	<keyword>Obstructive Lung Disease</keyword>
	<keyword>Lung Diseases</keyword>
</DOC>